

Avdoralimab

Cat. No.:	HY-P99450
CAS No.:	2226393-85-5
Target:	Complement System
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Avdoralimab (IPH 5401) is a fully human IgG _k monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research ^[1] .
In Vitro	Avdoralimab (IPH 5401) selectively blocks the C5a-C5aR1 interaction and its downstream signaling in human myeloid cells. In vitro, C5aR1 blockade with Avdoralimab (10-30 µg/mL) inhibits C5a-induced neutrophil activation. Avdoralimab blocks the neutrophil activation induced by very high concentrations of C5a. Avdoralimab also inhibits the C5a-induced migration of neutrophils in vitro ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	In mice with a knock in for human C5aR1 (HuC5aR1 KI mice), Avdoralimab blocks the infiltration of neutrophils and monocytes, prevents albumin release in broncho-alveolar lavage fluid (BALF) and limits C5a-induced acute lung injury (ALI) histopathological features ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Julien Carvelli, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 Dec;588(7836):146-150.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA